Dr. Patel on the Benefits of a Multidisciplinary Approach for Patients With Stage III Lung CancerNovember 1st 2014
Jyoti D. Patel, MD, thoracic oncologist, Northwestern University Feinberg School of Medicine, discusses the benefits of multidisciplinary approach for the treatment of patients with stage III disease.
Dr. Spigel Discusses Results from a Phase III Study Exploring Eribulin in NSCLCNovember 1st 2014
David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.
Nivolumab Plus Chemotherapy Shows Similar Efficacy to Nivolumab Monotherapy in NSCLCNovember 1st 2014
Nivolumab combined with platinum-based doublet chemotherapy achieved a manageable safety profile with clinical efficacy that was similar to single-agent nivolumab in patients with advanced NSCLC.
Phase II Study Shows Promising Efficacy for Nivolumab in Advanced NSCLCOctober 31st 2014
The PD-1 immune checkpoint inhibitor nivolumab achieved an ORR of 15% with a median duration of response that was not yet reached at a median 11-month follow-up for patients with advanced, refractory NSCLC.
Afatinib Extends OS by Approximately 1 Year in Subgroup of NSCLCOctober 31st 2014
First-line afatinib (Gilotrif) improved overall survival (OS) by about 1 year in patients with advanced nonâ€“small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions according to results from the LUX-Lung 3 and the LUX-Lung 6 phase III randomized trials.
Dr. Govindan on the Potential for AlectinibOctober 31st 2014
Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.
Post-Operative Radiation Therapy Improves Overall Survival in NSCLC PatientsOctober 31st 2014
Patients with NSCLC who received postoperative radiation therapy lived 4 months longer on average than patients who did not receive radiation but who had the same disease site, tumor histology, and treatment criteria, according to a large retrospective study.
Dr. Camidge on Inhibiting Initial Activating EGFR Mutations and the T790M Resistance MutationOctober 31st 2014
D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.
Dr. Sequist Discusses the OS Analysis of LUX-Lung 3 and LUX-Lung 6October 30th 2014
Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.